TW201334779A - 糖尿病的治療藥 - Google Patents

糖尿病的治療藥 Download PDF

Info

Publication number
TW201334779A
TW201334779A TW102102886A TW102102886A TW201334779A TW 201334779 A TW201334779 A TW 201334779A TW 102102886 A TW102102886 A TW 102102886A TW 102102886 A TW102102886 A TW 102102886A TW 201334779 A TW201334779 A TW 201334779A
Authority
TW
Taiwan
Prior art keywords
group
therapeutic
prophylactic agent
diabetes
glucose metabolism
Prior art date
Application number
TW102102886A
Other languages
English (en)
Chinese (zh)
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of TW201334779A publication Critical patent/TW201334779A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102102886A 2012-01-27 2013-01-25 糖尿病的治療藥 TW201334779A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27

Publications (1)

Publication Number Publication Date
TW201334779A true TW201334779A (zh) 2013-09-01

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102102886A TW201334779A (zh) 2012-01-27 2013-01-25 糖尿病的治療藥

Country Status (15)

Country Link
US (1) US20150005506A1 (2)
EP (1) EP2808018B1 (2)
JP (1) JP5924699B2 (2)
KR (1) KR20140134266A (2)
CN (1) CN104066430A (2)
AR (1) AR089812A1 (2)
AU (1) AU2013212865A1 (2)
BR (1) BR112014017902A2 (2)
CA (1) CA2862602A1 (2)
HK (1) HK1201209A1 (2)
IN (1) IN2014DN05972A (2)
MX (1) MX2014008484A (2)
RU (1) RU2014134845A (2)
TW (1) TW201334779A (2)
WO (1) WO2013111870A1 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
EP3417858B8 (en) 2016-02-19 2020-12-30 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142494T1 (de) * 1990-11-30 1996-09-15 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
US8557831B2 (en) * 2004-07-21 2013-10-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
WO2007018687A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
US20070167454A1 (en) 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
WO2007062028A2 (en) * 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (ja) 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
KR20150024919A (ko) 2006-11-13 2015-03-09 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
SG183721A1 (en) * 2007-11-27 2012-09-27 Ardea Biosciences Inc Novel compounds and compositions and methods of use
CA2718709C (en) * 2008-03-31 2016-08-09 C & C Research Laboratories Heterocyclic derivatives
CA2722624C (en) * 2008-04-30 2017-03-21 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
CA2725047A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
CN102256488A (zh) * 2008-10-19 2011-11-23 理查德·J·约翰逊 伴随代谢失衡慢性肾病的治疗组合物和治疗方法
US20120219536A1 (en) * 2009-08-24 2012-08-30 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
PE20170306A1 (es) * 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
RU2013103366A (ru) * 2010-06-25 2014-07-27 Тейдзин Фарма Лимитед Терапевтическое средство с замедленным высвобождением для гипертонии и почечной дисфункции

Also Published As

Publication number Publication date
IN2014DN05972A (2) 2015-06-26
JP5924699B2 (ja) 2016-05-25
CA2862602A1 (en) 2013-08-01
EP2808018A4 (en) 2015-07-15
BR112014017902A2 (pt) 2017-08-22
MX2014008484A (es) 2014-10-14
JPWO2013111870A1 (ja) 2015-05-11
EP2808018B1 (en) 2018-03-14
KR20140134266A (ko) 2014-11-21
CN104066430A (zh) 2014-09-24
HK1201209A1 (en) 2015-08-28
WO2013111870A1 (ja) 2013-08-01
US20150005506A1 (en) 2015-01-01
RU2014134845A (ru) 2016-03-20
AR089812A1 (es) 2014-09-17
AU2013212865A1 (en) 2014-08-14
EP2808018A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
TW201334779A (zh) 糖尿病的治療藥
CN104981242A (zh) 肿瘤溶解综合征的治疗药和预防药
UA100119C2 (uk) Застосування 3-альфа-андростандіолу в поєднанні з агоністом 5-ht1а для лікування сексуальної дисфункції
CN102223882B (zh) 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂
US11497748B2 (en) Method for activating AMPK and the use of adenine
JP5680412B2 (ja) レオヌリンの使用およびその組成物
JP6499634B2 (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
TWI777059B (zh) 肌肉減少症之預防劑及治療劑
JP7357380B2 (ja) 肥満関連代謝疾患の改善剤
JP2004244409A (ja) 糖尿病の発症予防薬
JPWO2007007757A1 (ja) ＰＰＡＲγアゴニストを含有する医薬組成物
JP2014513689A (ja) 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
US20100324081A1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
JP2020143037A (ja) 糖尿病合併心不全の治療用医薬組成物
KR20100017460A (ko) 피피에이알 감마 작용물질로 인한 부작용의 예방에 유용한 조성물
JPWO2001013911A1 (ja) 高血圧性細動脈障害抑制剤
JP6861726B2 (ja) 糖尿病性腎症の治療薬または予防薬
TW202547551A (zh) 降低血脂之組合物及其用途
WO2010098475A1 (ja) 摂食障害予防及び治療剤
WO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
JP2007530643A (ja) 複素環化合物と抗酸化剤との組合わせ、および肥満症を処置するためのその使用
JP2008179574A (ja) ピペラジン誘導体を有効成分とする糖化最終産物形成阻害剤
JP2008273859A (ja) 腎機能障害を持つ心不全患者を治療するためのコハク酸シベンゾリンを有効成分とする不整脈治療剤
CN110141571A (zh) 血红素在防治糖尿病及其并发症的应用
JPWO2019225722A1 (ja) 代謝改善剤